NuCana Valuation Multiples

NuCana is valued at $3M as of November 2026. In the last fiscal year, NuCana EBITDA was ($40M).

NuCana Overview

About NuCana

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.


Founded

1997

HQ

United Kingdom

Employees

22

Website

nucana.com

Financials (Last FY)

Revenue: -
EBITDA: ($40M)

Market Cap

$3M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

NuCana Financials

NuCana reported last fiscal year revenue of - and negative EBITDA of ($40M).

In the same fiscal year, NuCana generated ($40M) in EBITDA losses and had net loss of ($39M).


NuCana P&L

In the most recent fiscal year, NuCana reported revenue of - and EBITDA of ($40M).

NuCana is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for NuCana
LTMLast FY2025202620272028
EBITDA-($40M)($40M)
Net Profit($39M)($39M)($39M)
Net Debt-($31M)-

Financial data powered by Morningstar, Inc.

NuCana Stock Performance

NuCana has current market cap of $3M.

Market Cap Evolution


NuCana's stock price is $0.82.

NuCana has an EPS (earnings per share) of $-9.31.

See more trading valuation data for NuCana
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3M-7.7%---$-9.31

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

NuCana Valuation Multiples

NuCana Financial Valuation Multiples

As of November 19, 2026, NuCana has market cap of $3M.

NuCana has a P/E ratio of (0.1x).

LTMLast FY2025202620272028
P/E(0.1x)(0.1x)(0.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified NuCana Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

NuCana Operational KPIs

NuCana's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.2M for the same period.

Access forward-looking KPIs for NuCana
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$1.2M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
ODI Pharma$3M$248K0.9x-12.4x-
Institute of Biomedical-($239K)--(14.5x)-
Apimeds Pharmaceuticals-($6M)--(2.2x)-
Genxone$584K($429K)4.8x-(6.6x)-
Spago Nanomedical$43K($3M)20.3x-(0.3x)(0.3x)
Liminatus Pharma-($10M)--(0.2x)-
Scinai Immunotherapeutics$1M($7M)8.4x-(1.7x)-
ExpreS2ion Biotech$361K($4M)1.0x-(0.1x)-

This data is available for Pro users. Sign up to see all NuCana competitors and their valuation data.

Start Free Trial

NuCana VC Funding History

Before going public, NuCana raised $114M in total equity funding, across 2 rounds.


NuCana Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Apr-14Series BScottish Investment Bank; Sofinnova Investments$57M-NuCana BioMed, an Edinburgh-based biopharmaceutical company founded in 2008 by CEO Hugh Griffith and Executive Chairman Chris Wood, develops improved versions of existing chemotherapy drugs using its proprietary ProTide technology, which adds a phosphoramidate moiety to nucleoside analogues to enhance activity and safety by bypassing certain cellular activation barriers. The company's lead product, Acelarin (NUC-1031), a gemcitabine ProTide, showed encouraging Phase I results in pretreated solid tumor patients, with over half achieving stable disease or tumor shrinkage. NuCana's pipeline also includes NUC-3373, a floxuridine ProTide in preclinical development, with plans to advance additional programs. On April 10, 2014, NuCana completed a $57 million Series B financing led by new investor Sofinnova Ventures (U.S.), which provided about half the round, alongside substantial participation from largest shareholder Sofinnova Partners (France) and existing investors Morningside Ventures, Alida Capital International, and Scottish Investment Bank. This brought total funding to about $77 million since inception, following a $10.4 million Series A in November 2011 led by Sofinnova Partners. The proceeds fund expansion of Acelarin's clinical program, including two registration trials in pancreatic, ovarian, biliary cancer, and squamous cell non-small cell lung cancer; a Phase I combination study for NUC-3373; and clinic entry for two more programs, supporting operations into mid- to late 2016. New board members include Jim Healy from Sofinnova Ventures and Gerald Chan from Morningside. The round reflects strong investor confidence in NuCana's founders, who previously built and sold Bioenvision to Genzyme for $345 million in 2007 after developing clofarabine for pediatric leukemia. Investors emphasized the platform's potential across multiple products and indications rather than single assets, positioning NuCana to challenge standard nucleoside-based cancer treatments.
Apr-14Series BSofinnova Partners; 5Y Capital; Alida Capital International; Sofinnova Investments; Scottish Enterprise$57M-NuCana BioMed Ltd is an Edinburgh-based biopharmaceutical company developing ProTide technology, a platform that adds a phosphoramidate moiety to oncologic nucleosides to improve their activity and safety. The company's lead product is Acelarin, which was in Phase I clinical trials for solid tumors, with data showing over half of pretreated patients achieving stable disease or tumor shrinkage. In April 2014, NuCana completed a Series B financing of $57 million led by Sofinnova Ventures, with participation from Sofinnova Partners (the largest shareholder), Alida Capital International, Morningside Ventures, and the Scottish Investment Bank. The financing was sized to support at least one Phase III trial of Acelarin and enable the company to advance additional programs including NUC-3373, a floxuridine ProTide in preclinical development, through clinical stages. CEO Hugh Griffith stated the round would fund the company into mid to late 2016. The company had raised approximately $77 million in total funding by this round. The company's valuation was not disclosed at the time of the financing announcement.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About NuCana

When was NuCana founded?NuCana was founded in 1997.
Where is NuCana headquartered?NuCana is headquartered in United Kingdom.
How many employees does NuCana have?As of today, NuCana has over 22 employees.
Is NuCana publicly listed?Yes, NuCana is a public company listed on Nasdaq.
What is the stock symbol of NuCana?NuCana trades under NCNA ticker.
When did NuCana go public?NuCana went public in 2017.
Who are competitors of NuCana?NuCana main competitors include ODI Pharma, Institute of Biomedical, Apimeds Pharmaceuticals, Genxone, Spago Nanomedical, Liminatus Pharma, Scinai Immunotherapeutics, ExpreS2ion Biotech, Redhill Biopharma, Gelteq.
What is the current market cap of NuCana?NuCana's current market cap is $3M.
Is NuCana profitable?No, NuCana is not profitable.
What is the current net income of NuCana?NuCana's last 12 months net income is ($39M).
How many companies NuCana has acquired to date?NuCana hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies NuCana has invested to date?NuCana hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to NuCana

Lists including NuCana

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial